Published in Parkinsonism Relat Disord on January 01, 2003
Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology (Berl) (2008) 0.96
Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate. J Cereb Blood Flow Metab (2010) 0.84
Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. PLoS One (2010) 0.82
Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.79
Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology (Berl) (2010) 0.78
Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Behav Pharmacol (2016) 0.75
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology (2014) 2.14
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord (2012) 1.98
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 1.94
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord (2007) 1.72
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet (2005) 1.71
Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther (2007) 1.69
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord (2013) 1.62
Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord (2006) 1.50
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord (2008) 1.43
Affective theory of mind in patients with Parkinson's disease. Psychiatry Clin Neurosci (2013) 1.41
Diagnosis, assessment and management of delusional jealousy in Parkinson's disease with and without dementia. Neurol Sci (2012) 1.39
Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging (2006) 1.26
Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology (2011) 1.23
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.20
Clinical features associated with ictal osmophobia in migraine. Neurol Sci (2014) 1.19
RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) (2008) 1.17
Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci (2002) 1.14
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci U S A (2011) 1.09
Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov Disord (2011) 1.08
Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One (2012) 1.06
Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol (2009) 1.05
Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord (2011) 1.04
Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease. J Clin Neurophysiol (2003) 1.03
Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement Geriatr Cogn Disord (2003) 1.00
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients. Autism Res Treat (2012) 0.97
Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol (2011) 0.96
Theory of Mind in Parkinson's disease. Behav Brain Res (2011) 0.94
Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord (2009) 0.94
Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood (2002) 0.93
Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J (2002) 0.93
Decision making in de novo Parkinson's disease. Mov Disord (2010) 0.92
Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Ther Adv Psychopharmacol (2013) 0.92
Cerebellar ataxia with complete clinical recovery and resolution of MRI lesions related to central pontine myelinolysis: case report and literature review. Case Rep Neurol (2010) 0.90
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases. Neuropediatrics (2012) 0.90
Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study. Mov Disord (2008) 0.90
Progression of brain atrophy in the early stages of Parkinson's disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. Hum Brain Mapp (2014) 0.90
Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry (2003) 0.90
Activity-based diary for Parkinson's disease. Clin Neuropharmacol (2002) 0.90
Analysis of adult neurogenesis: evidence for a prominent "non-neurogenic" DCX-protein pool in rodent brain. PLoS One (2013) 0.90
Crystal engineering yields crystals of cyclophilin D diffracting to 1.7 A resolution. Acta Crystallogr D Biol Crystallogr (2005) 0.89
The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. J Clin Exp Neuropsychol (2012) 0.89
A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol (2013) 0.89
Case-control study of multiple system atrophy. Mov Disord (2005) 0.88
Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet (2003) 0.88
Expanding the clinical phenotype of DYT5 mutations: is multiple system atrophy a possible one? Neurology (2013) 0.88
Affective symptoms and cognitive functions in Parkinson's disease. J Neurol Sci (2012) 0.87
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. Neuropsychiatr Dis Treat (2008) 0.86
Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice. Behav Pharmacol (2008) 0.86
Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome. Neurol Sci (2013) 0.86
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord (2009) 0.86
Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol (2013) 0.85
Bilateral thalamic infarct caused by spontaneous vertebral artery dissection in pre-eclampsia with HELLP syndrome: a previously unreported association. J Stroke Cerebrovasc Dis (2012) 0.85
Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS One (2011) 0.85
Decreased and increased cortical activation coexist in de novo Parkinson's disease. Exp Neurol (2010) 0.84
Iowa gambling task in Parkinson's disease. J Clin Exp Neuropsychol (2010) 0.84
Abnormal response to photic stimulation in juvenile myoclonic epilepsy: an EEG-fMRI study. Epilepsia (2014) 0.84
Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol (2002) 0.84
Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease : a motor fMRI study under controlled conditions. Neuroradiology (2011) 0.84
Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J Neurol (2012) 0.83
Molecular recognition at the active site of catechol-o-methyltransferase: energetically favorable replacement of a water molecule imported by a bisubstrate inhibitor. Angew Chem Int Ed Engl (2009) 0.83
Parkinson's disease and pathological gambling: results from a functional MRI study. Mov Disord (2010) 0.83
Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord (2010) 0.83
Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading. Clin Neuropharmacol (2002) 0.83
Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. J Neurol (2010) 0.82
Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. Parkinsonism Relat Disord (2013) 0.82
Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Mov Disord (2007) 0.82
How aware are migraineurs of their triggers? Headache (2013) 0.82
Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett (2010) 0.82
Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. Chemistry (2011) 0.82
Postpartum headache due to spontaneous cervical artery dissection. Headache (2011) 0.82
Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. Neuroimage (2011) 0.81
Mapping cortical degeneration in ALS with magnetization transfer ratio and voxel-based morphometry. PLoS One (2013) 0.81
Levetiracetam-responsive myoclonus in spinocerebellar ataxia type 15. Mov Disord (2013) 0.81
Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. Curr Neurovasc Res (2013) 0.81
Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Org Biomol Chem (2003) 0.81
Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. Mov Disord (2012) 0.81
From aberrant salience to jumping to conclusions: dopaminergic pathways to delusions in Parkinson disease. J Clin Psychopharmacol (2013) 0.81
Molecular implications of the human glutathione transferase A-4 gene (hGSTA4) polymorphisms in neurodegenerative diseases. Mutat Res (2005) 0.80
The association between motor subtypes and alexithymia in de novo Parkinson's disease. J Neurol (2010) 0.80
Event-based prospective memory in newly diagnosed, drug-naive Parkinson's disease patients. J Int Neuropsychol Soc (2011) 0.79
Alzheimer and his disease: a brief history. Neurol Sci (2010) 0.79
Alteration of affective Theory of Mind in amnestic mild cognitive impairment. J Neuropsychol (2012) 0.79
Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett (2007) 0.79
The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease. Neurosci Lett (2010) 0.79
Apomorphine hydrochloride for the treatment of Parkinson's disease. Expert Rev Neurother (2015) 0.78
Orbital and ventromedial prefrontal cortex functioning in Parkinson's disease: neuropsychological evidence. Brain Cogn (2012) 0.78
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. Parkinsonism Relat Disord (2006) 0.78